Coverage
-
November 12, 2014
Braintree Laboratories Inc. has asked the U.S. Supreme Court to consider whether the Federal Circuit must defer to a district court's factual findings for claim construction, urging the justices to review its generic colon cleanser patent dispute, which it says hinges on the justices' forthcoming decision in Teva Pharmaceuticals USA v. Sandoz Inc.
5 other articles on this case.
View all »